Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors

Merestinib is an oral multi-kinase inhibitor targeting a limited number of oncokinases including MET, AXL, RON and MKNK1/2. Here, we report that merestinib inhibits neurotrophic receptor tyrosine kinases NTRK1/2/3 which are oncogenic drivers in tumors bearing NTRK fusion resulting from chromosomal r...

Descripción completa

Detalles Bibliográficos
Autores principales: Konicek, Bruce W., Capen, Andrew R., Credille, Kelly M., Ebert, Philip J., Falcon, Beverly L., Heady, Gary L., Patel, Bharvin K.R., Peek, Victoria L., Stephens, Jennifer R., Stewart, Julie A., Stout, Stephanie L., Timm, David E., Um, Suzane L., Willard, Melinda D., Wulur, Isabella H., Zeng, Yi, Wang, Yong, Walgren, Richard A., Betty Yan, Sau-Chi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862616/
https://www.ncbi.nlm.nih.gov/pubmed/29568395
http://dx.doi.org/10.18632/oncotarget.24488

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862616/
https://www.ncbi.nlm.nih.gov/pubmed/29568395
http://dx.doi.org/10.18632/oncotarget.24488

Ejemplares similares